Heart disease is the No 1 cause of death among people with Type 2 diabetes. There is also striking evidence that diabetes is related to obesity. Among Indians, particularly, the problem of central obesity, or fat deposition around the stomach area, is high. This central obesity is largely responsible for poor glucose control and also has a direct link to heart disease.
Initially, diabetes treatment was only about controlling elevated glucose levels, but now the treatment options look beyond glucose control. The most recent class of drugs approved and now available in India affect multiple factors associated with diabetes.
Jaynish's doctor, for example, prescribed him a new antidiabetic drug called empagliflozin. This drug belongs to a new class of antidiabetic drugs that have a unique mechanism of action. They throw out glucose (sugar) in the urine, bringing about a rapid reduction in blood glucose. At the same time, they bring about a small but significant reduction in weight and help control the blood pressure better. Jaynish's physician has now been able to reduce his insulin dose, helping him maintain good glucose control by relying on only oral antidiabetic tablets.
There was no solution for this until the recent advanced diabetes treatment solution substantiated by the EMPA study that is acknowledged by leading diabetologists and cardiologists.
Consultant endocrinologist, PD Hinduja Hospital & Medical Research Centre, Mahim, Mumbai
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
